Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17275112 | 0.80 | HSD17B10 (0.35) | HPGDRAB9A | |
| SCHEMBL1699448 | 0.78 | — | — | |
| SCHEMBL1699436 | 0.77 | — | — | |
| SCHEMBL1699655 | 0.77 | PTGDR2 (0.31) | PTGDR2 | |
| SCHEMBL15093251 | 0.77 | CXCR2 (0.33) | — | |
| SCHEMBL15093541 | 0.76 | TBXA2R (0.31) | PTGDR2 | |
| SCHEMBL1699761 | 0.72 | PTGDR2 (0.36) | PTGDR2SMN1; SMN2 | |
| SCHEMBL15093735 | 0.72 | CXCR2 (0.32) | HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL10272007 | 0.69 | KDM4E (0.32) | HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL10272115 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588450-A1 | NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS | Gilead Sciences, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012003497-A1 | NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |